Design, Synthesis, and Biological Evaluation of Triazolyl- and Triazinyl-Quinazolinediones as Potential Antitumor Agents

Table 1

In vitro antitumor activity of the tested compounds.

Compound number	IC50 µM
	HepG2	HCT116
7a	9.24 ± 0.33	99.43 ± 4.2
7c	3.20 ± 0.11	11.74 ± 0.67
8a	4.53 ± 0.12	2.21 ± 0.09
8b	23.72 ± .1.9	4.75 ± 0.18
8c	2.63 ± 0.13	1.57 ± 0.06
8f	118.1 ± 5.6	206.6 ± 9.5
8j	2.52 ± 0.69	30.93 ± 1.41
12d	13.53 ± 0.71	6.59 ± 0.27
12e	24.54 ± 1.6	7.70 ± 0.38
12g	14.39 ± 0.8	109.3 ± 7.1
Staurosporin	7.18 ± 0.32	11.26 0.81